Neurodegenerative Disease Management
Donanemab for early symptomatic AD in the UK-indicated population: safety and efficacy in those who are non-carriers or heterozygous for APOE ε4
Trial in peopleInterventions
Papers by Jennifer A. Zimmer
2 results
- Alzheimer's & Dementia
Further data to address the Alzheimer's coverage with evidence development questions
ReviewInterventions